Lundbeck's Phase IV THRIVE Trial Results Show Promise for Eptinezumab in Migraine Treatment #Denmark #Lundbeck #Valby #Vyepti #Eptinezumab

Lundbeck Celebrates Marketing Authorization for Innovative Migraine Treatment Vyepti® in Japan #Japan #Tokyo #Lundbeck #migraine_prevention #Eptinezumab